Compile Data Set for Download or QSAR
Report error Found 10951 with Last Name = 'swanson' and Initial = 'm'
TargetTransient receptor potential cation channel subfamily V member 1(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163243(4-(2-Trifluoromethyl-phenyl)-piperazine-1-carboxyl...)
Affinity DataEC50:  5.26E+3nMAssay Description:Effective concentration against human transient receptor potential vanilloid 1 receptor (n=3)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163238(4-Pyridin-4-yl-piperazine-1-carboxylic acid (4-chl...)
Affinity DataEC50:  3.60E+3nMAssay Description:Effective concentration against rat transient receptor potential vanilloid 1 receptor (n=6)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163240(4-(2-Trifluoromethyl-phenyl)-piperazine-1-carboxyl...)
Affinity DataEC50:  1.28E+3nMAssay Description:Effective concentration against rat transient receptor potential vanilloid 1 receptor (n=3)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163232(4-(2-Trifluoromethyl-phenyl)-piperazine-1-carboxyl...)
Affinity DataEC50:  7.29E+3nMAssay Description:Effective concentration against rat transient receptor potential vanilloid 1 receptor (n=3)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163240(4-(2-Trifluoromethyl-phenyl)-piperazine-1-carboxyl...)
Affinity DataEC50:  1.16E+3nMAssay Description:Effective concentration against human transient receptor potential vanilloid 1 receptor (n=3)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163231(4-Pyridin-3-yl-piperazine-1-carboxylic acid (4-tri...)
Affinity DataEC50:  2.67E+3nMAssay Description:Effective concentration against rat transient receptor potential vanilloid 1 receptor (n=3)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163235(4-o-Tolyl-piperidine-1-carboxylic acid (4-trifluor...)
Affinity DataEC50:  1.93E+3nMAssay Description:Effective concentration against human transient receptor potential vanilloid 1 receptor (n=2)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163238(4-Pyridin-4-yl-piperazine-1-carboxylic acid (4-chl...)
Affinity DataEC50:  7.24E+3nMAssay Description:Effective concentration against human transient receptor potential vanilloid 1 receptor (n=6)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163223(1-(4-Trifluoromethyl-phenyl)-3-[1-(3-trifluorometh...)
Affinity DataEC50: >1.00E+4nMAssay Description:Effective concentration against human transient receptor potential vanilloid 1 receptor (n=6); InactiveMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163229(4-(2-Trifluoromethyl-phenyl)-piperazine-1-carboxyl...)
Affinity DataEC50:  275nMAssay Description:Effective concentration against rat transient receptor potential vanilloid 1 receptor (n=4)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163229(4-(2-Trifluoromethyl-phenyl)-piperazine-1-carboxyl...)
Affinity DataEC50:  618nMAssay Description:Effective concentration against human transient receptor potential vanilloid 1 receptor (n=3)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163243(4-(2-Trifluoromethyl-phenyl)-piperazine-1-carboxyl...)
Affinity DataEC50:  8.30E+3nMAssay Description:Effective concentration against rat transient receptor potential vanilloid 1 receptor (n=6)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163220(3-Methyl-3'',4'',5'',6''-tetrahydro-2''H-[2,4'']bi...)
Affinity DataEC50:  1.96E+3nMAssay Description:Effective concentration against rat transient receptor potential vanilloid 1 receptor (n=2)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTransient receptor potential cation channel subfamily V member 1(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50163235(4-o-Tolyl-piperidine-1-carboxylic acid (4-trifluor...)
Affinity DataEC50:  1.72E+3nMAssay Description:Effective concentration against rat transient receptor potential vanilloid 1 receptor (n=2)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetHistamine H3 receptor(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50346201((4-Isopropyl-piperazin-1-yl)-(6-piperidin-1-ylmeth...)
Affinity DataKd:  6.31nMAssay Description:Antagonist activity at histamine H3 receptor in rat cortical hemispheres assessed as inhibition of forskolin stimulated cAMP accumulation after 6 hrsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2011
Entry Details Article
PubMed
TargetHistamine H3 receptor(Rat)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50346208((1-isopropylpiperidin-4-yl)(4-(piperidin-1-ylmethy...)
Affinity DataKd:  1.82nMAssay Description:Antagonist activity at histamine H3 receptor in rat cortical hemispheres assessed as inhibition of forskolin stimulated cAMP accumulation after 6 hrsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2011
Entry Details Article
PubMed
TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622070(US20230312550, Example 30)
Affinity DataKon:  0.000220M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622092(US20230312550, Example 52)
Affinity DataKon:  0.000190M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622163(US20230312550, Example 123)
Affinity DataKoff:  3.00E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622220(US20230312550, Example 180)
Affinity DataKoff:  5.60E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622058(US20230312550, Example 18)
Affinity DataKon:  0.0000590M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622175(US20230312550, Example 135)
Affinity DataKoff:  1.70E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622089(US20230312550, Example 49)
Affinity DataKd:  0.0200nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622193(US20230312550, Example 153)
Affinity DataKd:  0.0150nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622213(US20230312550, Example 173)
Affinity DataKd:  0.510nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622217(US20230312550, Example 177)
Affinity DataKd:  0.560nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622105(US20230312550, Example 65)
Affinity DataKoff:  6.70E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622114(US20230312550, Example 74)
Affinity DataKoff:  1.10E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622141(US20230312550, Example 101)
Affinity DataKon:  0.0000250M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622150(US20230312550, Example 110)
Affinity DataKon:  0.0000500M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622180(US20230312550, Example 140)
Affinity DataKon:  0.000160M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622234(US20230312550, Example 194)
Affinity DataKon:  0.0000680M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622073(US20230312550, Example 33)
Affinity DataKd:  0.0590nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622129(US20230312550, Example 89)
Affinity DataKd:  0.0530nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622182(US20230312550, Example 142)
Affinity DataKd:  0.0280nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622050(US20230312550, Example 10)
Affinity DataKon:  0.0000560M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622113(US20230312550, Example 73)
Affinity DataKon:  0.000160M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622169(US20230312550, Example 129)
Affinity DataKoff:  1.40E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622193(US20230312550, Example 153)
Affinity DataKoff:  5.30E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622210(US20230312550, Example 170)
Affinity DataKoff:  1.00E+7s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622212(US20230312550, Example 172)
Affinity DataKon:  0.0000760M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622233(US20230312550, Example 193)
Affinity DataKon:  0.000120M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622048(US20230312550, Example 8)
Affinity DataKon:  0.0000340M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622089(US20230312550, Example 49)
Affinity DataKon:  0.000170M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622181(US20230312550, Example 141)
Affinity DataKon:  0.0000780M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622239(US20230312550, Example 199)
Affinity DataKon:  0.000260M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622090(US20230312550, Example 50)
Affinity DataKd:  0.0710nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622208(US20230312550, Example 168)
Affinity DataKd:  0.0320nMAssay Description:Table 1: Compounds were tested in a biochemical inhibition assay using human Fibroblast activation protein alpha (hFAP) enzyme at 2.4 pM FAC (Protero...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622079(US20230312550, Example 39)
Affinity DataKon:  0.000160M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622083(US20230312550, Example 43)
Affinity DataKon:  0.0000190M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 10951 total ) | Next | Last >>
Jump to: